Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Double Blind Phase	STARTED	Birtamimab (24 mg/kg) + Standard of Care	139
Double Blind Phase	STARTED	Placebo + Standard of Care	68
Double Blind Phase	COMPLETED	Birtamimab (24 mg/kg) + Standard of Care	97
Double Blind Phase	COMPLETED	Placebo + Standard of Care	49
Double Blind Phase	NOT COMPLETED	Birtamimab (24 mg/kg) + Standard of Care	42
Double Blind Phase	NOT COMPLETED	Placebo + Standard of Care	19
Open Label Extension Phase	STARTED	Birtamimab (24 mg/kg) + Standard of Care	92
Open Label Extension Phase	STARTED	Placebo + Standard of Care	44
Open Label Extension Phase	COMPLETED	Birtamimab (24 mg/kg) + Standard of Care	0
Open Label Extension Phase	COMPLETED	Placebo + Standard of Care	0
Open Label Extension Phase	NOT COMPLETED	Birtamimab (24 mg/kg) + Standard of Care	92
Open Label Extension Phase	NOT COMPLETED	Placebo + Standard of Care	44

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04973137/flow